Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Gains Rights to ViroNovative IP for Use in Respiratory Viral Panel

NEW YORK (GenomeWeb News) – Luminex said today that it has signed an agreement with Dutch diagnostic developer ViroNovative that gives it worldwide rights to use the company’s human metapneumovirus intellectual property in its xTAG Respiratory Viral Panel.
 
Luminex said that its distributors and end-user customers around the world also have rights to use the ViroNovative IP under the terms of the agreement.
 
"Having this license as part of our xTAG RVP assay is important to us as it allows our customers to use this cutting-edge test without the need to individually secure rights to this intellectual property," said Jeremy Bridge-Cook, vice president of Luminex Molecular Diagnostics, in a statement.  
 
Luminex received 510(k) clearance for the xTAG RVP assay from the US Food and Drug Administration in January. The test was cleared for the detection of 12 viruses and viral subtypes, including hMPV.
 
ViroNovative is an Erasmus University spin-out that is focused on developing diagnostics, vaccines, and antivirals for hMPV. The virus, first characterized in 2001 by company founders, causes flu-like symptoms and is thought to be the second-most-common cause of lower respiratory infection in young children.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.